MoneyKurma closes new fund at €250mKurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies. more ➔
https://doi.org/10.3390/ijms241411791Breast CancerGenentech takes over Regor’s RGT-419...Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ … more ➔
Spima TherapeuticsPartnershipSpima Therapeutics starts with global lice...SPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001 more ➔
GourmeyNovel FoodEFSA updates guidelines on cultured protei...The EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority … more ➔
Ovid Therapeutics - Jeremy LevinStatementLong version of The BIOSECURE Act: The Wes...By Jeremy Levin, D.Phil, MB BChir more ➔
Asabys PartnersFinancingAsabys Partners close €180m Sabadell Asa...Asabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech. more ➔
SR-TigitFinancingGenespire raises US$52m in Series B roundItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia … more ➔
Image by freepikAMRAMR Accelerator urges long-term fundingAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving … more ➔
CDC/Phil_ImagesVaccinesVicebio Ltd cashes in US$100m in Series B...London-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline progra … more ➔
Brenus Pharma SAFinancingFrench Brenus AS closes US$25m financingFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens. more ➔
https://doi.org/10.3390/ijms241411791
Spima Therapeutics
Gourmey
Ovid Therapeutics - Jeremy Levin
Asabys Partners
SR-Tigit
Image by freepik
CDC/Phil_Images
Brenus Pharma SA